11:33 AM EST, 02/24/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.)

Summit Therapeutics' ( SMMT ) shares fell 12% in recent Monday trading after the company reported a Q4 non-GAAP net loss of $0.07 per diluted share, widening from the loss of $0.04 a year earlier.

Analysts polled by FactSet expected a loss of $0.08.

The biopharmaceutical company didn't report any revenue.

The company reported cash, cash equivalents and short-term investments of $412.3 million as of Dec. 31, up from $186.2 million a year earlier.

Price: 19.43, Change: -2.69, Percent Change: -12.16